Spots Global Cancer Trial Database for Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Official Title: A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer
Study ID: NCT00472693
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact Details
Name: Angela DeMichele, M.D.
Affiliation: Abramson Cancer Center of University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
